Spectral Med Inc Total Liabilities
Spectral Med Inc total liabilities. Based on the latest financial reports, Spectral Med Inc (EDT) has total liabilities worth CA$76.79 Million CAD (≈ $55.55 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Spectral Med Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Spectral Med Inc (1992–2024)
Total liabilities of Spectral Med Inc from 1992 to 2024. This chart illustrates how Spectral Med Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Spectral Med Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Spectral Med Inc Competitors by Total Liabilities
The table below lists competitors of Spectral Med Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AIRA Capital Public Company Limited
BK:AIRA
|
Thailand | ฿5.21 Billion |
|
Quang Viet Enterprise Co Ltd
TW:4438
|
Taiwan | NT$8.73 Billion |
|
PAMT CORP
NASDAQ:PAMT
|
USA | $487.43 Million |
|
Zwack Unicum Likoripari es Kereskedelmi Nyrt.
BUD:ZWACK
|
Hungary | Ft9.95 Billion |
|
D2L Inc
TO:DTOL
|
Canada | CA$157.78 Million |
|
Superior Uniform Group Inc
NASDAQ:SGC
|
USA | $213.77 Million |
|
Smart Sand Inc
NASDAQ:SND
|
USA | $108.97 Million |
|
TSS, Inc. Common Stock
NASDAQ:TSSI
|
USA | $95.03 Million |
Liability Composition Analysis (1992–2024)
This chart breaks down Spectral Med Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EDT asset base.
Liquidity & Leverage Metrics
Spectral Med Inc Total Liabilities Ratios Explained
Spectral Med Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spectral Med Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spectral Med Inc (1992–2024)
The table below shows the annual total liabilities of Spectral Med Inc from 1992 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$32.87 Million ≈ $23.77 Million |
+51.03% |
| 2023-12-31 | CA$21.76 Million ≈ $15.74 Million |
+49.55% |
| 2022-12-31 | CA$14.55 Million ≈ $10.53 Million |
+94.73% |
| 2021-12-31 | CA$7.47 Million ≈ $5.41 Million |
-15.40% |
| 2020-12-31 | CA$8.83 Million ≈ $6.39 Million |
+405.84% |
| 2019-12-31 | CA$1.75 Million ≈ $1.26 Million |
+187.64% |
| 2018-12-31 | CA$607.00K ≈ $439.09K |
-1.30% |
| 2017-12-31 | CA$615.00K ≈ $444.88K |
-51.88% |
| 2016-12-31 | CA$1.28 Million ≈ $924.49K |
-57.77% |
| 2015-12-31 | CA$3.03 Million ≈ $2.19 Million |
-0.53% |
| 2014-12-31 | CA$3.04 Million ≈ $2.20 Million |
-18.71% |
| 2013-12-31 | CA$3.74 Million ≈ $2.71 Million |
+85.98% |
| 2012-12-31 | CA$2.01 Million ≈ $1.46 Million |
+17.52% |
| 2011-12-31 | CA$1.71 Million ≈ $1.24 Million |
+10.59% |
| 2010-12-31 | CA$1.55 Million ≈ $1.12 Million |
-57.79% |
| 2009-12-31 | CA$3.67 Million ≈ $2.65 Million |
+20.86% |
| 2008-12-31 | CA$3.03 Million ≈ $2.19 Million |
+19.59% |
| 2007-12-31 | CA$2.54 Million ≈ $1.84 Million |
+8.10% |
| 2006-12-31 | CA$2.35 Million ≈ $1.70 Million |
-78.31% |
| 2005-12-31 | CA$10.82 Million ≈ $7.83 Million |
+5.53% |
| 2004-12-31 | CA$10.25 Million ≈ $7.42 Million |
-3.97% |
| 2003-12-31 | CA$10.68 Million ≈ $7.72 Million |
+4.68% |
| 2002-12-31 | CA$10.20 Million ≈ $7.38 Million |
+3.18% |
| 2001-12-31 | CA$9.89 Million ≈ $7.15 Million |
+29.38% |
| 2000-12-31 | CA$7.64 Million ≈ $5.53 Million |
+10.74% |
| 1999-12-31 | CA$6.90 Million ≈ $4.99 Million |
+9.52% |
| 1998-12-31 | CA$6.30 Million ≈ $4.56 Million |
+57.50% |
| 1997-12-31 | CA$4.00 Million ≈ $2.89 Million |
+17.65% |
| 1996-12-31 | CA$3.40 Million ≈ $2.46 Million |
+54.55% |
| 1995-12-31 | CA$2.20 Million ≈ $1.59 Million |
+37.50% |
| 1994-12-31 | CA$1.60 Million ≈ $1.16 Million |
+77.78% |
| 1993-12-31 | CA$900.00K ≈ $651.05K |
+28.57% |
| 1992-12-31 | CA$700.00K ≈ $506.37K |
-- |
About Spectral Med Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device … Read more